Corporate Updates

nContact EPi-Sense device receives CE mark

nContact has received CE mark approval for its fourth generation EPi-Sense guided-coagulation device with VisiTrax for the treatment of cardiac arrhythmias, including atrial fibrillation. The EPi-Sense device features epicardial sensing electrodes designed to allow electrophysiologists and cardiothoracic surgeons to navigate the epicardium and locate areas for linear epicardial ablation. The device provides visible access to the posterior of the atrium through a trans-diaphragmatic pericardial window, and allows doctors to create visible and non-conductive linear lesions on a beating heart. The device is scheduled to be commercially available throughout Europe in the fourth quarter of 2011.

Click to comment

Leave a Reply

Your email address will not be published.

Most Popular





Get Heard Portal


eHealth Event Report



To Top